SciVision Biotech Inc. Stock price

Equities

1786

TW0001786002

Medical Equipment, Supplies & Distribution

End-of-day quote Taiwan S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
95.2 TWD +0.21% Intraday chart for SciVision Biotech Inc. +5.43% +22.68%
Sales 2022 557M 17.42M Sales 2023 713M 22.29M Capitalization 5.25B 164M
Net income 2022 142M 4.44M Net income 2023 178M 5.56M EV / Sales 2022 6.07 x
Net cash position 2022 206M 6.43M Net cash position 2023 397M 12.41M EV / Sales 2023 6.81 x
P/E ratio 2022
28.2 x
P/E ratio 2023
32.2 x
Employees -
Yield 2022
3.69%
Yield 2023
3.22%
Free-Float 65.19%
More Fundamentals * Assessed data
Dynamic Chart
SciVision Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
SciVision Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
SciVision Biotech Inc.(TWSE:1786) added to S&P Global BMI Index CI
SciVision Biotech Inc.'s Product, Cross-Linked Hyaluronic Acid Synovial Fluid Supplement ?Hyajoint Plus? Obtains Medical Device License CI
SciVision Biotech Inc. Announces Corporate Governance Officer Changes CI
SciVision Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
SciVision Biotech Inc. Approves Cash Dividend, Payable on August 18, 2023 CI
SciVision Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
SciVision Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
SciVision Biotech Inc.(TWSE:1786) dropped from S&P Global BMI Index CI
SciVision Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
SciVision Biotech Inc. Announces Cash Dividend, Payable on August 18, 2022 CI
SciVision Biotech Inc. Announces Hyaluronic Acid Flexotron Forte (1%) Has Obtained Medical Device License CI
SciVision Biotech Inc. Announces Executive Changes CI
SciVision Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day+0.21%
1 week+5.43%
Current month+6.85%
1 month+8.68%
3 months+23.16%
6 months+14.56%
Current year+22.68%
More quotes
1 week
89.90
Extreme 89.9
97.60
1 month
86.40
Extreme 86.4
97.60
Current year
73.20
Extreme 73.2
97.60
1 year
64.60
Extreme 64.6
99.50
3 years
38.80
Extreme 38.8
99.50
5 years
33.36
Extreme 33.3553
99.50
10 years
30.63
Extreme 30.6342
102.95
More quotes
Managers TitleAgeSince
Chief Executive Officer - 02-06-13
Director of Finance/CFO - -
Director of Finance/CFO - 03-07-27
Members of the board TitleAgeSince
Director/Board Member - -
Chief Executive Officer - 02-06-13
Director/Board Member - 11-06-08
More insiders
Date Price Change Volume
24-03-27 95.2 +0.21% 1 103 015
24-03-27 95 +1.82% 1,179,929
24-03-26 93.3 -0.32% 546,717
24-03-25 93.6 +3.43% 1,484,450
24-03-22 90.5 +0.78% 380,710

End-of-day quote Taiwan S.E., March 27, 2024

More quotes
SciVision Biotech Inc is principally engaged in the manufacturing and distribution of hyaluronic acid medical supplies. The Company primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The Company is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The Company operates its business in the Americas, Europe, Asia, Middle East and Africa.
More about the company
  1. Stock
  2. Equities
  3. Stock SciVision Biotech Inc. - Taiwan S.E.